In a panel of 39 cell lines, including 7 WT KRAS cell lines, 24 mutant KRAS cell lines, and 8 WT KRAS cell lines with alterations in upstream signaling, originating from lung, colorectal, or pancreatic cancers, BI-2865 inhibited KRAS activation and downstream signaling in both KRAS WT and mutant models. This evidence concerns the gene KRAS and pancreatic neoplasm.